Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REX-001 versus placebo for diabetic critical limb ischemia with ischemic rest pain
NL-OMON47803Phase 3Withdrawn
- Sponsor
- Ixaka
- Start
- Jan 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans comparing REX-001 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Jan 2017; status: withdrawn.
02
Drugs
rexmyelocel-T
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON47803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47803.